Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167565 | 0.79 | HCRTR2 (0.60) | ALDH1A1HCRTR2POLBHCRTR1ITK | |
| SCHEMBL1167055 | 0.78 | HCRTR2 (0.65) | HCRTR2HCRTR1 | |
| SCHEMBL1166697 | 0.74 | HCRTR2 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL1166840 | 0.72 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL1167197 | 0.72 | HCRTR2 (0.45) | ALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL1166320 | 0.72 | KDM4E (0.45) | ALDH1A1MAPTHCRTR2HCRTR1ITK | |
| SCHEMBL1167087 | 0.71 | HCRTR2 (0.70) | ALDH1A1HCRTR2POLBHCRTR1SMN1; SMN2 | |
| SCHEMBL1166791 | 0.70 | CYP1A2 (0.51) | ALDH1A1MAPTRAB9APOLBSMN1; SMN2 | |
| SCHEMBL1166403 | 0.69 | FPR2 (0.44) | ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1166775 | 0.69 | LPAR1 (0.49) | ALDH1A1MAPTPOLBSCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | ALDH1A1 96/4885MAPT 2198/4885RAB9A 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.